Langen Karl-Josef, Hamacher Kurt, Weckesser Matthias, Floeth Frank, Stoffels Gabriele, Bauer Dagmar, Coenen Heinz H, Pauleit Dirk
Institute of Medicine, Research Center Jülich, D-52425 Jülich, Germany.
Nucl Med Biol. 2006 Apr;33(3):287-94. doi: 10.1016/j.nucmedbio.2006.01.002.
O-(2-[18F]fluoroethyl)-L-tyrosine (FET) is a promising tracer for PET that has demonstrated convincing results especially in the diagnostics of brain tumors. In contrast to other radiolabeled amino acids, it can be produced with high efficiency and distributed in a satellite concept like the widely used 2-[18F]fluoro-2-deoxy-D-glucose. Although FET is not incorporated into proteins, it shows high uptake in cerebral gliomas and in extracranial squamous cell carcinomas owing to increased transport. The tracer exhibits high in vivo stability, low uptake in inflammatory tissue and suitable uptake kinetics for clinical imaging, which indicates that it may become a new standard tracer for PET. In this article, the present knowledge on the uptake mechanisms and the clinical applications of FET are reviewed and the clinical perspectives are discussed.
O-(2-[18F]氟乙基)-L-酪氨酸（FET）是一种很有前景的正电子发射断层扫描（PET）示踪剂，尤其在脑肿瘤诊断方面已取得令人信服的结果。与其他放射性标记氨基酸不同，它能够高效合成，并以类似于广泛使用的2-[18F]氟-2-脱氧-D-葡萄糖的卫星概念进行分布。尽管FET不会掺入蛋白质中，但由于转运增加，它在脑胶质瘤和颅外鳞状细胞癌中显示出高摄取。该示踪剂在体内具有高稳定性，在炎症组织中摄取低，并且具有适合临床成像的摄取动力学，这表明它可能成为PET的一种新的标准示踪剂。本文综述了关于FET摄取机制和临床应用的现有知识，并讨论了其临床前景。
